The SAD treatman alone has a potential of peak revenues of around 1.6 billion usd p.a. in the USA alone. The market introduction is forecasted after potential phase 3 in 2026. There are no side effects for this treatment. Cash reach for the company is forecasted after the both readouts. Very interesting. Maybe an outlicensing deal after sucessful phase 2 or a takeover
- Forums
- ASX - By Stock
- BNO
- Massive undervalued
Massive undervalued, page-2
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BNO (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online